Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis

Thrombosis Research

Volumn 99, Issue 2, 2000, Pages 111-117

  Fujii, Masato ^a   Hayakawa, Hiroshi ^b   Urano, Tetsumei ^a   Sato, Atsuhiko ^c   Chida, Kingo ^a   Nakamura, Hirotoshi ^a   Takada, Akikazu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

^c Kyoto Preventive Center   (Japan)

Author keywords

Bronchoalveolar lavage; Cuboidal epithelial cell; Idiopathic pulmonary fibrosis; Procoagulant activity; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCOAGULABILITY; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

ADULT; AGED; ANTICOAGULANTS; ANTIGENS; BLOOD COAGULATION TESTS; BRONCHOALVEOLAR LAVAGE FLUID; EPITHELIAL CELLS; FEMALE; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; LUNG; MALE; MIDDLE AGED; PULMONARY FIBROSIS; REGRESSION ANALYSIS; SERINE PROTEINASE INHIBITORS; THROMBOPHILIA; THROMBOPLASTIN;

EID: 0034661333     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00237-1     Document Type: Article

References (17)

1. Crystal R.G., Bitterman P.B., Rennard S.I., Hance A.J., Keogh B.A. Interstitial lung disease of unknown cause. disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts) N Engl J Med. 310:1984;154-166.
2. Chapman H.A., Allen C.L., Stone O.L. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis. 133:1986;437-443.
3. Kotani I., Sato A., Hayakawa H., Urano T., Takada Y., Takada A. Increased procoagulant and antifibrinolytic activities in the lung with idiopathic pulmonary fibrosis. Thromb Res. 77:1995;493-504.
4. Imokawa S., Sato A., Hayakawa H., Kotani M., Urano T., Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Crit Care Med. 156:1997;631-636.
5. Grinnel F., Feld M., Minter D. Fibroblast adhesion to fibrinogen and fibrin substrata. requirement for cold-insoluble globulin (plasma fibronectin) Cell. 19:1980;517-525.
6. Nemerson Y. Tissue factor and hemostasis. Blood. 71:1998;1-8.
7. Edgington T.S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 66:1991;67-79.
8. Broze G.J. Jr., Girard T.J., Novotny W.F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry. 29:1990;7539-7546.
9. De Moerloose P., Hamilton J.A., Sewell W.A., Vadas M.A., Mackay I.R. Pertussigen in vivo enhances antigen specific production in vitro of lymphokine that stimulates macrophage procoagulant activity and plasminogen activator. J Immunol. 137:1986;3528-3533.
10. Werling R.N., Zacharski L.R., Kisiel W., Bajaj S.P., Memoli V.A., Rosseau S.M. Distribution of tissue factor pathway inhibitor in normal and pathologic tissue. Thromb Haemost. 69:1993;366-369.
11. Idell S., Pendurthi U., Pueblitz S., Koenig K., Williams T., Rao L.V.M. Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits. Thromb Haemost. 79:1998;649-655.
12. Ameri A., Kupuswamy M.N., Basu S., Bajaj S.P. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 79:1992;3219-3226.
13. Zhang Y., Lee T.C., Guillemin B., Yu M.-C., Rom W.N. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 150:1993;4188-4196.
14. Falciani M., Gori A.M., Fedi S., Chiarugi L., Simonetti I., Dabizzi R.P., Prisco D., Pepe G., Abbate R., Gensini G.F., Serneri G.G.N. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost. 79:1998;495-499.
15. van't Veer C., Mann K.G. Regulation of tissue factor initiated thorombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J. Biol Chem. 272:1997;4367-4377.
16. Caplice N.M., Mueske C.S., Kleppe L.S., Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 98:1998;1051-1057.
17. Erlich J.H., Apostolopoulos J., Wun T.-C., Kretzmer K.K., Holdsworth S.R., Tipping P.G. Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis. J Clin Invest. 98:1996;325-335.